The Disintegration and Dissolution of Nabumetone Dispersible Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Disintegration and Dissolution of Nabumetone Dispersible Tablets
Nabumetone was complexed with β-cyclodextrin, and a 23 factorial design was used to prepare dispersible tablets containing the drug or its complex.The authors analyzed the effects of complexation as well as the levels of ammonium bicarbonate and crospovidone on tablet wetting time (WT), disintegration time (DT), and percent dissolution efficiency at 60 min (%DE60).


Pharmaceutical Technology


Results and discussion

Solubility results. The phase-solubility diagram obtained was classified as AL type because the apparent solubility of nabumetone increased linearly (R2 5 0.968) with β-CD concentration over the entire concentration range studied, thereby suggesting the formation of a water soluble complex. A slope value of less than 1.00 indicated that an inclusion complex in a molar stiochiometric ratio of 1:1 was formed between the drug and β-CD in solution. The stability constant (411.76 M–1), computed from the slope and intercept of the phase solubility diagram, indicated considerable interaction between the hydrophobic drug and the hydrophobic cavity of β-CD. The values of stability constants described in the literature ranged from 100 to 20,000 M–1 for drug β-CD complexes (22).


Figure 1: FTIR spectra of (a) nabumetone, (b) b-cyclodextrin, (c) physical mixture, and (d) kneaded complex. All figures are courtesy of the authors.
Spectral analysis. The IR spectra of the drug, β-CD, and the kneaded complex are portrayed in Figure 1. The IR spectra of the complex revealed that many functional groups of the drug might have interacted with β-CD. A low-intensity peak assignable to the drug carbonyl stretching appeared to have shifted from 1705 cm–1 to 1690 cm–1 in the spectra of the kneaded complex. This displacement and reduction of the peak intensity suggested the possibility of the hydrogen-bond formation between the -C=O of the guest molecule and the hydroxyl functional group of β-CD. The spectra of the complex showed that the broad β-CD band between 3900 and 2900 cm–1 overlapped the drug characteristic peaks as a result of -CH- aromatic stretching and -CH- aliphatic stretching of the same region. A similar overlapping of the drug characteristic peaks by the β-CD band on complexation has been published (23).

The drug peaks at 1645 cm–1 resulting from skeletal vibrations of -C=C- bonds in the aromatic ring decreased in the intensities in the spectra of the complex, thereby indicating considerable drug and β-CD interaction. These spectral observations suggest that the vibration and bending of the drug molecule might be restricted because of complexation as the aromatic ring of the drug was inserted in the β-CD cavity.


Figure 2: DSC thermogram of (a) nabumetone, (b) b-cyclodextrin, (c) physical mixture, and (d) kneaded complex. All figures are courtesy of the authors.
Differential scanning calorimetry.. The endothermic peak at 80 °C in the DSC scan of the drug represented the melting-point transition of the crystalline drug (see Figure 2). The broad band that appeared between 110 °C and 140 °C in the thermogram of β-CD can be attributed to a loss of water or a molecular dehydration process. The reduced area of the drug endothermic peak in the DSC spectra of the complex indicated considerable interaction between the drug and β-CD, which substantially reduced the drug crystallinity. This reduction in the band area and the peak intensity indicates a reduction in the energy required for the melting transition. The β-CD dehydration band in the DSC scan of the kneaded product shifted to lower temperature between 90 and 130 °C. A similar shift in the β-CD dehydration band on complexation has been recorded (23).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here